Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function
Identifieur interne : 000D11 ( Istex/Corpus ); précédent : 000D10; suivant : 000D12Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function
Auteurs : Yasmin Singh ; Lynette S. Sawyer ; Linda S. Pinkoski ; Kent W. Dupuis ; Jocelyn C. Hsu ; Lily Lin ; Laurence CorashSource :
- Transfusion [ 0041-1132 ] ; 2006-07.
English descriptors
- Teeft :
- Amotosalen, Amotosalen container, Antithrombotic protein activities, Antithrombotic proteins, Aptt, Assay, Babesia microti, Baseline, Baseline activity, Baxter healthcare corp, Behring clot timer, Biological assays, Blood centers, Blood component therapy, Blood components, Blood mintz, Blood products, Blood safety, Blood supply, Bluetongue virus, Borrelia burgdorferi, Broad range, Broad spectrum, Burgdorferi, California department, Causes syphilis, Cell membrane, Cerus corp, Chimpanzee infectivity model, Chromogenic substrate, Coagulation, Coagulation analyzer, Coagulation factor activity, Coagulation factors, Coagulation function, Coagulation parameter, Colony formation, Compound adsorption device, Cruzi, Dade behring, Dhbv, Diagnostica stago, Diarrhea virus, Falciparum, Galactosidase production, Hanson, Health services, Helinx technology, Hepatitis, High levels, Human adenovirus, Human parvovirus, Human platelet, Illumination container, Illumination device, Inactivates, Inactivation, Infectious dose, Infectivity, Inoculated, Inoculated cells, Instrumentation laboratory, Intercept blood system, July, Klebsiella pneumoniae, Least logs, Leukocyte depletion, Luria bertani, Methylene, Microti, Nonenveloped, Nonenveloped viruses, Pallidum, Partial thromboplastin time, Pathogen, Pathogen inactivation, Pathogen inactivation studies, Photochemical inactivation, Photochemical treatment, Plasma, Plasma function, Plasma function studies, Plasma unit, Plasma units, Plasmodium falciparum, Plastic container, Platelet, Plts, Processing cycle, Prothrombin time, Reference range, Replicates, Respiratory syndrome coronavirus, Same dose, Same illumination device, Several countries, Test pathogens, Test plasma samples, Titer, Transfusion, Transfusion volume, Trypanosoma cruzi, Ultraviolet light, Viable organisms, Virus, West nile virus, Yersinia enterocolitica.
Abstract
BACKGROUND: The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function. STUDY DESIGN AND METHODS: Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm2 long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities. RESULTS: The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; Klebsiella pneumoniae, greater than 7.4; Staphylococcus epidermidis and Yersinia enterocolitica, greater than 7.3; Treponema pallidum, greater than 5.9; Borrelia burgdorferi, greater than 10.6; Plasmodium falciparum, 6.9; Trypanosoma cruzi, greater than 5.0; and Babesia microti, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin. CONCLUSION: PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.
Url:
DOI: 10.1111/j.1537-2995.2006.00867.x
Links to Exploration step
ISTEX:00BDD775AF6850E69CB3CAE9F34F44041508D8D5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title><author><name sortKey="Singh, Yasmin" sort="Singh, Yasmin" uniqKey="Singh Y" first="Yasmin" last="Singh">Yasmin Singh</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Sawyer, Lynette S" sort="Sawyer, Lynette S" uniqKey="Sawyer L" first="Lynette S." last="Sawyer">Lynette S. Sawyer</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Pinkoski, Linda S" sort="Pinkoski, Linda S" uniqKey="Pinkoski L" first="Linda S." last="Pinkoski">Linda S. Pinkoski</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Dupuis, Kent W" sort="Dupuis, Kent W" uniqKey="Dupuis K" first="Kent W." last="Dupuis">Kent W. Dupuis</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Hsu, Jocelyn C" sort="Hsu, Jocelyn C" uniqKey="Hsu J" first="Jocelyn C." last="Hsu">Jocelyn C. Hsu</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Lin, Lily" sort="Lin, Lily" uniqKey="Lin L" first="Lily" last="Lin">Lily Lin</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Corash, Laurence" sort="Corash, Laurence" uniqKey="Corash L" first="Laurence" last="Corash">Laurence Corash</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:00BDD775AF6850E69CB3CAE9F34F44041508D8D5</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1537-2995.2006.00867.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-FW6611XX-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000D11</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title><author><name sortKey="Singh, Yasmin" sort="Singh, Yasmin" uniqKey="Singh Y" first="Yasmin" last="Singh">Yasmin Singh</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Sawyer, Lynette S" sort="Sawyer, Lynette S" uniqKey="Sawyer L" first="Lynette S." last="Sawyer">Lynette S. Sawyer</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Pinkoski, Linda S" sort="Pinkoski, Linda S" uniqKey="Pinkoski L" first="Linda S." last="Pinkoski">Linda S. Pinkoski</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Dupuis, Kent W" sort="Dupuis, Kent W" uniqKey="Dupuis K" first="Kent W." last="Dupuis">Kent W. Dupuis</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Hsu, Jocelyn C" sort="Hsu, Jocelyn C" uniqKey="Hsu J" first="Jocelyn C." last="Hsu">Jocelyn C. Hsu</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Lin, Lily" sort="Lin, Lily" uniqKey="Lin L" first="Lily" last="Lin">Lily Lin</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author><author><name sortKey="Corash, Laurence" sort="Corash, Laurence" uniqKey="Corash L" first="Laurence" last="Corash">Laurence Corash</name><affiliation><mods:affiliation>From Cerus Corp., Concord, California.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">46</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1168">1168</biblScope><biblScope unit="page" to="1177">1177</biblScope><biblScope unit="page-count">10</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2006-07">2006-07</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Amotosalen</term><term>Amotosalen container</term><term>Antithrombotic protein activities</term><term>Antithrombotic proteins</term><term>Aptt</term><term>Assay</term><term>Babesia microti</term><term>Baseline</term><term>Baseline activity</term><term>Baxter healthcare corp</term><term>Behring clot timer</term><term>Biological assays</term><term>Blood centers</term><term>Blood component therapy</term><term>Blood components</term><term>Blood mintz</term><term>Blood products</term><term>Blood safety</term><term>Blood supply</term><term>Bluetongue virus</term><term>Borrelia burgdorferi</term><term>Broad range</term><term>Broad spectrum</term><term>Burgdorferi</term><term>California department</term><term>Causes syphilis</term><term>Cell membrane</term><term>Cerus corp</term><term>Chimpanzee infectivity model</term><term>Chromogenic substrate</term><term>Coagulation</term><term>Coagulation analyzer</term><term>Coagulation factor activity</term><term>Coagulation factors</term><term>Coagulation function</term><term>Coagulation parameter</term><term>Colony formation</term><term>Compound adsorption device</term><term>Cruzi</term><term>Dade behring</term><term>Dhbv</term><term>Diagnostica stago</term><term>Diarrhea virus</term><term>Falciparum</term><term>Galactosidase production</term><term>Hanson</term><term>Health services</term><term>Helinx technology</term><term>Hepatitis</term><term>High levels</term><term>Human adenovirus</term><term>Human parvovirus</term><term>Human platelet</term><term>Illumination container</term><term>Illumination device</term><term>Inactivates</term><term>Inactivation</term><term>Infectious dose</term><term>Infectivity</term><term>Inoculated</term><term>Inoculated cells</term><term>Instrumentation laboratory</term><term>Intercept blood system</term><term>July</term><term>Klebsiella pneumoniae</term><term>Least logs</term><term>Leukocyte depletion</term><term>Luria bertani</term><term>Methylene</term><term>Microti</term><term>Nonenveloped</term><term>Nonenveloped viruses</term><term>Pallidum</term><term>Partial thromboplastin time</term><term>Pathogen</term><term>Pathogen inactivation</term><term>Pathogen inactivation studies</term><term>Photochemical inactivation</term><term>Photochemical treatment</term><term>Plasma</term><term>Plasma function</term><term>Plasma function studies</term><term>Plasma unit</term><term>Plasma units</term><term>Plasmodium falciparum</term><term>Plastic container</term><term>Platelet</term><term>Plts</term><term>Processing cycle</term><term>Prothrombin time</term><term>Reference range</term><term>Replicates</term><term>Respiratory syndrome coronavirus</term><term>Same dose</term><term>Same illumination device</term><term>Several countries</term><term>Test pathogens</term><term>Test plasma samples</term><term>Titer</term><term>Transfusion</term><term>Transfusion volume</term><term>Trypanosoma cruzi</term><term>Ultraviolet light</term><term>Viable organisms</term><term>Virus</term><term>West nile virus</term><term>Yersinia enterocolitica</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND: The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function. STUDY DESIGN AND METHODS: Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm2 long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities. RESULTS: The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; Klebsiella pneumoniae, greater than 7.4; Staphylococcus epidermidis and Yersinia enterocolitica, greater than 7.3; Treponema pallidum, greater than 5.9; Borrelia burgdorferi, greater than 10.6; Plasmodium falciparum, 6.9; Trypanosoma cruzi, greater than 5.0; and Babesia microti, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin. CONCLUSION: PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>transfusion</json:string><json:string>amotosalen</json:string><json:string>pathogen</json:string><json:string>coagulation</json:string><json:string>inactivation</json:string><json:string>platelet</json:string><json:string>nonenveloped</json:string><json:string>infectivity</json:string><json:string>photochemical treatment</json:string><json:string>july</json:string><json:string>microti</json:string><json:string>inoculated</json:string><json:string>falciparum</json:string><json:string>methylene</json:string><json:string>cruzi</json:string><json:string>assay</json:string><json:string>plts</json:string><json:string>inactivates</json:string><json:string>replicates</json:string><json:string>hanson</json:string><json:string>burgdorferi</json:string><json:string>high levels</json:string><json:string>dhbv</json:string><json:string>aptt</json:string><json:string>pallidum</json:string><json:string>nonenveloped viruses</json:string><json:string>pathogen inactivation</json:string><json:string>california department</json:string><json:string>diagnostica stago</json:string><json:string>blood components</json:string><json:string>infectious dose</json:string><json:string>health services</json:string><json:string>plasma</json:string><json:string>coagulation factors</json:string><json:string>transfusion volume</json:string><json:string>respiratory syndrome coronavirus</json:string><json:string>blood products</json:string><json:string>coagulation function</json:string><json:string>dade behring</json:string><json:string>plasma units</json:string><json:string>baseline</json:string><json:string>blood safety</json:string><json:string>west nile virus</json:string><json:string>test plasma samples</json:string><json:string>broad range</json:string><json:string>bluetongue virus</json:string><json:string>intercept blood system</json:string><json:string>cerus corp</json:string><json:string>illumination device</json:string><json:string>plasma unit</json:string><json:string>amotosalen container</json:string><json:string>viable organisms</json:string><json:string>plasmodium falciparum</json:string><json:string>luria bertani</json:string><json:string>baxter healthcare corp</json:string><json:string>coagulation parameter</json:string><json:string>plasma function</json:string><json:string>human platelet</json:string><json:string>pathogen inactivation studies</json:string><json:string>titer</json:string><json:string>virus</json:string><json:string>hepatitis</json:string><json:string>plastic container</json:string><json:string>coagulation factor activity</json:string><json:string>borrelia burgdorferi</json:string><json:string>illumination container</json:string><json:string>processing cycle</json:string><json:string>human adenovirus</json:string><json:string>antithrombotic protein activities</json:string><json:string>yersinia enterocolitica</json:string><json:string>biological assays</json:string><json:string>galactosidase production</json:string><json:string>ultraviolet light</json:string><json:string>trypanosoma cruzi</json:string><json:string>colony formation</json:string><json:string>coagulation analyzer</json:string><json:string>instrumentation laboratory</json:string><json:string>klebsiella pneumoniae</json:string><json:string>behring clot timer</json:string><json:string>test pathogens</json:string><json:string>chromogenic substrate</json:string><json:string>several countries</json:string><json:string>babesia microti</json:string><json:string>partial thromboplastin time</json:string><json:string>compound adsorption device</json:string><json:string>diarrhea virus</json:string><json:string>least logs</json:string><json:string>plasma function studies</json:string><json:string>causes syphilis</json:string><json:string>inoculated cells</json:string><json:string>reference range</json:string><json:string>baseline activity</json:string><json:string>antithrombotic proteins</json:string><json:string>same dose</json:string><json:string>chimpanzee infectivity model</json:string><json:string>human parvovirus</json:string><json:string>blood centers</json:string><json:string>cell membrane</json:string><json:string>blood supply</json:string><json:string>broad spectrum</json:string><json:string>same illumination device</json:string><json:string>blood component therapy</json:string><json:string>helinx technology</json:string><json:string>prothrombin time</json:string><json:string>photochemical inactivation</json:string><json:string>leukocyte depletion</json:string><json:string>blood mintz</json:string></teeft></keywords><author><json:item><name>Yasmin Singh</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item><json:item><name>Lynette S. Sawyer</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item><json:item><name>Linda S. Pinkoski</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item><json:item><name>Kent W. Dupuis</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item><json:item><name>Jocelyn C. Hsu</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item><json:item><name>Lily Lin</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item><json:item><name>Laurence Corash</name><affiliations><json:string>From Cerus Corp., Concord, California.</json:string></affiliations></json:item></author><articleId><json:string>TRF00867</json:string></articleId><arkIstex>ark:/67375/WNG-FW6611XX-V</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>BACKGROUND: The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function. STUDY DESIGN AND METHODS: Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm2 long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities. RESULTS: The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; Klebsiella pneumoniae, greater than 7.4; Staphylococcus epidermidis and Yersinia enterocolitica, greater than 7.3; Treponema pallidum, greater than 5.9; Borrelia burgdorferi, greater than 10.6; Plasmodium falciparum, 6.9; Trypanosoma cruzi, greater than 5.0; and Babesia microti, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin. CONCLUSION: PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.</abstract><qualityIndicators><score>10</score><pdfWordCount>5945</pdfWordCount><pdfCharCount>40088</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>594 x 783 pts</pdfPageSize><pdfWordsPerPage>595</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>281</abstractWordCount><abstractCharCount>2054</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title><pmid><json:string>16836564</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Transfusion</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1537-2995</json:string></doi><issn><json:string>0041-1132</json:string></issn><eissn><json:string>1537-2995</json:string></eissn><publisherId><json:string>TRF</json:string></publisherId><volume>46</volume><issue>7</issue><pages><first>1168</first><last>1177</last><total>10</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>17-03-20039</json:string><json:string>1990s</json:string><json:string>2006</json:string><json:string>17-02-20042</json:string></date><geogName></geogName><orgName><json:string>Esoterix Laboratories</json:string><json:string>Haemonetics Corp.</json:string><json:string>California Department of Health Services, Richmond, CA Colony</json:string><json:string>Cerus Corp.</json:string><json:string>George King Biomedical, Inc.</json:string><json:string>Baxter Healthcare Corp.</json:string><json:string>MD Onyx Pharmaceuticals, Inc., Richmond</json:string><json:string>Hepadnavirus Testing Laboratories</json:string><json:string>From Cerus Corp.</json:string><json:string>Army Medical Research Acquisition Activity</json:string><json:string>California Department of Health Services, Richmond, CA HBV HCV DHBV MS</json:string><json:string>Aurora, CO</json:string><json:string>California Department of Health Services, Richmond, CA HTLV</json:string><json:string>University of California</json:string><json:string>California Department of Health Services, Richmond, CA K</json:string><json:string>State University</json:string><json:string>Instrumentation Laboratory Co</json:string><json:string>University of Washington</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Margaret Rheinschmidt</json:string><json:string>C.V. Hanson</json:string><json:string>Fort Detrick</json:string><json:string>Nova Biomedical</json:string><json:string>Sheila Lukehart</json:string><json:string>S. Sawyer</json:string><json:string>Lily Lin</json:string><json:string>Harvey Alter</json:string><json:string>Linda S. Pinkoski</json:string><json:string>Kent W. Dupuis</json:string><json:string>Robert Lane</json:string><json:string>Nichols</json:string><json:string>George Cimino</json:string><json:string>John Kinsey</json:string><json:string>Wesley Van Voorhis</json:string><json:string>Debbie Hanson</json:string><json:string>K. Bernard</json:string><json:string>Phillippe Grellier</json:string><json:string>Betsy Donnelly</json:string><json:string>Jorge Benach</json:string><json:string>Yasmin Singh</json:string><json:string>Adam Sampson-Johannes</json:string><json:string>Jocelyn C. Hsu</json:string><json:string>H. Heidrich</json:string><json:string>Jocelyn Smyers</json:string><json:string>Kristen Bernard</json:string><json:string>Septicemia</json:string></persName><placeName><json:string>Menlo Park</json:string><json:string>Durham</json:string><json:string>Nile</json:string><json:string>Marburg</json:string><json:string>Germany</json:string><json:string>United States</json:string><json:string>Braintree</json:string><json:string>KS</json:string><json:string>GA</json:string><json:string>Overland Park</json:string><json:string>NC</json:string><json:string>Seattle</json:string><json:string>Europe</json:string><json:string>Atlanta</json:string><json:string>Japan</json:string><json:string>America</json:string><json:string>Berkeley</json:string><json:string>New Zealand</json:string><json:string>CA</json:string><json:string>MA</json:string><json:string>France</json:string><json:string>WA</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Cerus Corp., 2411</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-FW6611XX-V</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - hematology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - cardiovascular system & hematology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1111/j.1537-2995.2006.00867.x</json:string></doi><id>00BDD775AF6850E69CB3CAE9F34F44041508D8D5</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FW6611XX-V/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FW6611XX-V/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-FW6611XX-V/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title><title level="a" type="short">PHOTOCHEMICAL TREATMENT OF PLASMA</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2006-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title><title level="a" type="short">PHOTOCHEMICAL TREATMENT OF PLASMA</title><author xml:id="author-0000"><persName><forename type="first">Yasmin</forename><surname>Singh</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Lynette S.</forename><surname>Sawyer</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Linda S.</forename><surname>Pinkoski</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Kent W.</forename><surname>Dupuis</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Jocelyn C.</forename><surname>Hsu</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Lily</forename><surname>Lin</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Laurence</forename><surname>Corash</surname></persName><affiliation><address><addrLine>From Cerus Corp.</addrLine><addrLine>Concord, California.</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">00BDD775AF6850E69CB3CAE9F34F44041508D8D5</idno><idno type="ark">ark:/67375/WNG-FW6611XX-V</idno><idno type="DOI">10.1111/j.1537-2995.2006.00867.x</idno><idno type="unit">TRF00867</idno><idno type="toTypesetVersion">file:TRF.TRF00867.pdf</idno></analytic><monogr><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="pISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><idno type="book-DOI">10.1111/(ISSN)1537-2995</idno><idno type="book-part-DOI">10.1111/trf.2006.46.issue-7</idno><idno type="product">TRF</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">46</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1168">1168</biblScope><biblScope unit="page" to="1177">1177</biblScope><biblScope unit="page-count">10</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2006-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">BACKGROUND: </hi> The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function.</p><p><hi rend="bold">STUDY DESIGN AND METHODS: </hi> Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm<hi rend="superscript">2</hi> long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities.</p><p><hi rend="bold">RESULTS:</hi> The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; <hi rend="italic">Klebsiella pneumoniae,</hi> greater than 7.4; <hi rend="italic">Staphylococcus epidermidis</hi> and <hi rend="italic">Yersinia enterocolitica</hi>, greater than 7.3; <hi rend="italic">Treponema pallidum</hi>, greater than 5.9; <hi rend="italic">Borrelia burgdorferi</hi>, greater than 10.6; <hi rend="italic">Plasmodium falciparum</hi>, 6.9; <hi rend="italic">Trypanosoma cruzi,</hi> greater than 5.0; and <hi rend="italic">Babesia microti</hi>, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin.</p><p><hi rend="bold">CONCLUSION:</hi> PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.</p></abstract><textClass><keywords rend="tocHeading1"><term>BLOOD COMPONENTS</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FW6611XX-V/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Inc</publisherName><publisherLoc>Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1537-2995</doi><issn type="print">0041-1132</issn><issn type="electronic">1537-2995</issn><idGroup><id type="product" value="TRF"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="TRANSFUSION">Transfusion</title></titleGroup></publicationMeta><publicationMeta level="part" position="07007"><doi origin="wiley">10.1111/trf.2006.46.issue-7</doi><numberingGroup><numbering type="journalVolume" number="46">46</numbering><numbering type="journalIssue" number="7">7</numbering></numberingGroup><coverDate startDate="2006-07">July 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="17" status="forIssue"><doi origin="wiley">10.1111/j.1537-2995.2006.00867.x</doi><idGroup><id type="unit" value="TRF00867"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="tocHeading1">BLOOD COMPONENTS</title></titleGroup><eventGroup><event type="firstOnline" date="2006-06-26"></event><event type="publishedOnlineFinalForm" date="2006-06-26"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-03"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1168">1168</numbering><numbering type="pageLast" number="1177">1177</numbering></numberingGroup><correspondenceTo>Yasmin Singh, PhD, Cerus Corp., 2411 Stanwell Drive, Concord, CA 94520; e‐mail: <email>yasmin_singh@cerus.com</email>.
</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:TRF.TRF00867.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received for publication September 2, 2005; revision received November 7, 2005, and accepted November 13, 2005.</unparsedEditorialHistory><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="6"></count><count type="formulaTotal" number="1"></count><count type="referenceTotal" number="49"></count><count type="wordTotal" number="5433"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title><title type="shortAuthors"><b>SINGH ET AL.</b></title><title type="short"><b>PHOTOCHEMICAL TREATMENT OF PLASMA</b></title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>Yasmin</givenNames><familyName>Singh</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>Lynette S.</givenNames><familyName>Sawyer</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#aff-1-1"><personName><givenNames>Linda S.</givenNames><familyName>Pinkoski</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#aff-1-1"><personName><givenNames>Kent W.</givenNames><familyName>Dupuis</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#aff-1-1"><personName><givenNames>Jocelyn C.</givenNames><familyName>Hsu</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#aff-1-1"><personName><givenNames>Lily</givenNames><familyName>Lin</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#aff-1-1"><personName><givenNames>Laurence</givenNames><familyName>Corash</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="US"><unparsedAffiliation>From Cerus Corp., Concord, California.</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>BACKGROUND: </b> The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function.</p><p><b>STUDY DESIGN AND METHODS: </b> Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm<sup>2</sup> long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities.</p><p><b>RESULTS:</b> The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; <i>Klebsiella pneumoniae,</i> greater than 7.4; <i>Staphylococcus epidermidis</i> and <i>Yersinia enterocolitica</i>, greater than 7.3; <i>Treponema pallidum</i>, greater than 5.9; <i>Borrelia burgdorferi</i>, greater than 10.6; <i>Plasmodium falciparum</i>, 6.9; <i>Trypanosoma cruzi,</i> greater than 5.0; and <i>Babesia microti</i>, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin.</p><p><b>CONCLUSION:</b> PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1" numbered="no"><p>These studies were supported in part by Cerus Corp., Baxter Healthcare Corp., and Grants DAMD17‐01‐20007, DAMD17‐02‐20042, and DAMD17‐03‐20039.</p></note><note xml:id="fn2" numbered="no"><p>The U.S. Army Medical Research Acquisition Activity (Fort Detrick, MD) is the awarding and administering acquisition office for Grants DAMD17‐01‐20007, DAMD17‐02‐20042, and DAMD17‐03‐20039. The contents of this report do not necessarily reflect the position or policy of the government and no official endorsement is implied by this award.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PHOTOCHEMICAL TREATMENT OF PLASMA</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title></titleInfo><name type="personal"><namePart type="given">Yasmin</namePart><namePart type="family">Singh</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lynette S.</namePart><namePart type="family">Sawyer</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Linda S.</namePart><namePart type="family">Pinkoski</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kent W.</namePart><namePart type="family">Dupuis</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jocelyn C.</namePart><namePart type="family">Hsu</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lily</namePart><namePart type="family">Lin</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurence</namePart><namePart type="family">Corash</namePart><affiliation>From Cerus Corp., Concord, California.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Inc</publisher><place><placeTerm type="text">Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2006-07</dateIssued><edition>Received for publication September 2, 2005; revision received November 7, 2005, and accepted November 13, 2005.</edition><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">6</extent><extent unit="formulas">1</extent><extent unit="references">49</extent><extent unit="linksCrossRef">0</extent><extent unit="words">5433</extent></physicalDescription><abstract lang="en">BACKGROUND: The INTERCEPT Blood System, a photochemical treatment (PCT) process, has been developed to inactivate pathogens in platelet concen‐trates. These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function. STUDY DESIGN AND METHODS: Jumbo (600 mL) plasma units were inoculated with high titers of test pathogens and treated with 150 µmol per L amotosalen and 3 J per cm2 long‐wavelength ultraviolet light. The viability of each pathogen before and after treatment was measured with biological assays. Plasma function was evaluated through measurement of coagulation factors and antithrombotic protein activities. RESULTS: The levels of inactivation expressed as log‐reduction were as follows: cell‐free human immunodeficiency virus‐1 (HIV‐1), greater than 6.8; cell‐associated HIV‐1, greater than 6.4; human T‐lymphotropic virus‐I (HTLV‐I), 4.5; HTLV‐II, greater than 5.7; hepatitis B virus (HBV) and hepatitis C virus, greater than 4.5; duck HBV, 4.4 to 4.5; bovine viral diarrhea virus, 6.0; severe acute respiratory syndrome coronavirus, 5.5; West Nile virus, 6.8; bluetongue virus, 5.1; human adenovirus 5, 6.8; Klebsiella pneumoniae, greater than 7.4; Staphylococcus epidermidis and Yersinia enterocolitica, greater than 7.3; Treponema pallidum, greater than 5.9; Borrelia burgdorferi, greater than 10.6; Plasmodium falciparum, 6.9; Trypanosoma cruzi, greater than 5.0; and Babesia microti, greater than 5.3. Retention of coagulation factor activity after PCT was expressed as the proportion of pretreatment (baseline) activity. Retention was 72 to 73 percent of baseline fibrinogen and Factor (F)VIII activity and 78 to 98 percent for FII, FV, FVII, F IX, FX, FXI, FXIII, protein C, protein S, antithrombin, and α2‐antiplasmin. CONCLUSION: PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion‐transmitted diseases in patients requiring plasma transfusion support.</abstract><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0041-1132</identifier><identifier type="eISSN">1537-2995</identifier><identifier type="DOI">10.1111/(ISSN)1537-2995</identifier><identifier type="PublisherID">TRF</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1168</start><end>1177</end><total>10</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Blood collection and transfusion in the United States in 1997</title></titleInfo><name type="personal"><namePart type="given">MT</namePart><namePart type="family">Sullivan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">McCullough</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GB</namePart><namePart type="family">Schreiber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EL</namePart><namePart type="family">Wallace</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sullivan MT, McCullough J, Schreiber GB, Wallace EL. Blood collection and transfusion in the United States in 1997. Transfusion 2002;42:1253‐60.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1253</start><end>60</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1253</start><end>60</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732‐47.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>732</start><end>47</end></extent></part><relatedItem type="host"><titleInfo><title>Anesthesiology</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>732</start><end>47</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population</title></titleInfo><name type="personal"><namePart type="given">RY</namePart><namePart type="family">Dodd</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EP4th</namePart><namePart type="family">Notari</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Stramer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population. Transfusion 2002;42:975‐9.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>975</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>975</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Why “safer than ever” may not be safe enough</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Barbara</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barbara J. Why “safer than ever” may not be safe enough. Transfus Med Hemother 2004;31(Suppl 1):2‐10.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>2</start><end>10</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Hemother</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>2</start><end>10</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Phelps</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Robbins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Liberti</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Phelps R, Robbins K, Liberti T, et al. Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004;44:929‐33.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>929</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>929</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Intermittent low‐level viremia in very early primary HIV‐1 infection</title></titleInfo><name type="personal"><namePart type="given">EW</namePart><namePart type="family">Fiebig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Heldebrant</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RI</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fiebig EW, Heldebrant CM, Smith RI, et al. Intermittent low‐level viremia in very early primary HIV‐1 infection. J Acquir Immune Defic Syndr 2005;39:133‐7.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>133</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>J Acquir Immune Defic Syndr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>133</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Virus inactivated single‐donor fresh plasma preparations</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Mohr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Lambrecht</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Knuever‐Hopf</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mohr H, Lambrecht B, Knuever‐Hopf J. Virus inactivated single‐donor fresh plasma preparations. Infusionsther Transfusionsmed 1992;19:79‐83.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>79</start><end>83</end></extent></part><relatedItem type="host"><titleInfo><title>Infusionsther Transfusionsmed</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>79</start><end>83</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Methylene blue‐treated fresh‐frozen plasma: what is its contribution to blood safety?</title></titleInfo><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Williamson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Cardigan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CV</namePart><namePart type="family">Prowse</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williamson LM, Cardigan R, Prowse CV. Methylene blue‐treated fresh‐frozen plasma: what is its contribution to blood safety? Transfusion 2003;43:1322‐9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1322</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1322</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Solvent/detergent‐treated plasma: a virus‐inactivated substitute for fresh frozen plasma</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Horowitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Bonomo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Prince</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent‐treated plasma: a virus‐inactivated substitute for fresh frozen plasma. Blood 1992;79:826‐31.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>826</start><end>31</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>826</start><end>31</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Inactivation of viruses found with plasma proteins</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Horowitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Horowitz B. Inactivation of viruses found with plasma proteins. Biotechnology 1991;19:417‐30.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>417</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnology</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>417</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization</title></titleInfo><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Wagner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Robinette</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Storry</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wagner SJ, Robinette D, Storry J, et al. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion 1994;34:521‐6.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>521</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>521</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Alford BL. Important new drug warning [monograph on the Internet].Watertown (MA): V.I. Technologies, Inc. Vitex); 2002. Available from: http://www.fda.gov/medwatch/safety/2002/plassd_deardoc.pdf</title></titleInfo><note type="citation/reference">Alford BL. Important new drug warning [monograph on the Internet]. Watertown (MA): V.I. Technologies, Inc. Vitex); 2002. Available from: http://www.fda.gov/medwatch/safety/2002/plassd_deardoc.pdf</note><name type="personal"><namePart type="given">BL</namePart><namePart type="family">Alford</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book</genre><originInfo><publisher>V.I. Technologies, Inc. Vitex)</publisher></originInfo><part><date>2002</date></part></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and costs</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Osselaer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Doyen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sonet</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Osselaer JC, Doyen C, Sonet A, et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and costs. Blood 2004;104:987a.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>987a</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>987a</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Fundamentals of the psoralen‐based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Wollowitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wollowitz S. Fundamentals of the psoralen‐based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(4 Suppl 11):4‐11.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>Suppl</number></detail><extent unit="pages"><start>4</start><end>11</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Hematol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>Suppl</number></detail><extent unit="pages"><start>4</start><end>11</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Pinna</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sampson‐Johannes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Clementi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pinna D, Sampson‐Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005;15:269‐76.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>269</start><end>76</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>269</start><end>76</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CV</namePart><namePart type="family">Hanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Alter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light. Transfusion 2005;45:580‐90.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>580</start><end>90</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>580</start><end>90</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>In vitro photochemical inactivation of cell‐associated human T‐cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Jauvin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RD</namePart><namePart type="family">Alfonso</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Guillemain</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jauvin V, Alfonso RD, Guillemain B, et al. In vitro photochemical inactivation of cell‐associated human T‐cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005;45:1151‐9.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1151</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1151</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Dikeman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Molini</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496‐504.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1496</start><end>504</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1496</start><end>504</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long‐wavelength UV</title></titleInfo><name type="personal"><namePart type="given">WC</namePart><namePart type="family">Van Voorhis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LK</namePart><namePart type="family">Barrett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RT</namePart><namePart type="family">Eastman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long‐wavelength UV. Antimicrob Agents Chemother 2003;47:475‐9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>475</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>475</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long‐wavelength ultraviolet irradiation</title></titleInfo><name type="personal"><namePart type="given">RT</namePart><namePart type="family">Eastman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LK</namePart><namePart type="family">Barrett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Dupuis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eastman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long‐wavelength ultraviolet irradiation. Transfusion 2005;45:1459‐63.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1459</start><end>63</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1459</start><end>63</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA</title></titleInfo><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Grass</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Hei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Metchette</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180‐8.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>2180</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>2180</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>A simple method of estimating fifty‐per cent endpoints</title></titleInfo><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Muench</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reed LJ, Muench H. A simple method of estimating fifty‐per cent endpoints. Am J Hyg 1938;27:493‐7.</note><part><date>1938</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>493</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Hyg</title></titleInfo><part><date>1938</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>493</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Quality of therapeutic plasma‐requirements for marketing authorization</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Heiden</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Seitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heiden M, Seitz R. Quality of therapeutic plasma‐requirements for marketing authorization. Thromb Res 2002;107 (Suppl. 1):S47‐51.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><detail type="issue"><caption>no.</caption><number>Suppl. 1</number></detail><extent unit="pages"><start>S47</start><end>51</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Res</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><detail type="issue"><caption>no.</caption><number>Suppl. 1</number></detail><extent unit="pages"><start>S47</start><end>51</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>In vitro characterization of solvent/detergent‐treated human plasma and of quarantine fresh frozen plasma</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Beeck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Hellstern</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beeck H, Hellstern P. In vitro characterization of solvent/detergent‐treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998;74(Suppl 1):219‐23.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>219</start><end>23</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>219</start><end>23</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>The molecular biology of the hepatitis B viruses</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Ganem</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HE</namePart><namePart type="family">Varmus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987;56:651‐93.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>651</start><end>93</end></extent></part><relatedItem type="host"><titleInfo><title>Annu Rev Biochem</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>651</start><end>93</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome</title></titleInfo><name type="personal"><namePart type="given">QL</namePart><namePart type="family">Choo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kuo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Weiner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome. Science 1989;244:359‐62.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>244</number></detail><extent unit="pages"><start>359</start><end>62</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>244</number></detail><extent unit="pages"><start>359</start><end>62</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Elimination of both cell‐free and cell‐associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Abe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yamada‐Ohnishi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Hirayama</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Abe H, Yamada‐Ohnishi Y, Hirayama J, et al. Elimination of both cell‐free and cell‐associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system. Transfusion 2000;40:1081‐7.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>1081</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>1081</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real‐time quantitative PCR</title></titleInfo><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Visconti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Pennington</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SF</namePart><namePart type="family">Garner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Visconti MR, Pennington J, Garner SF, et al. Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real‐time quantitative PCR. Blood 2004;103:1137‐9.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>1137</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>1137</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Persistence of HTLV‐I in blood components after leukocyte depletion</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Pennington</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GP</namePart><namePart type="family">Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Sutherland</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV‐I in blood components after leukocyte depletion. Blood 2002;100:677‐81.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>677</start><end>81</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>677</start><end>81</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Presence and significance of parvovirus B19 in blood and blood products</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Siegl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Cassinotti</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998;26:89‐94.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>89</start><end>94</end></extent></part><relatedItem type="host"><titleInfo><title>Biologicals</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>89</start><end>94</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Transfusion‐transmissible infections</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Vrielink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Reesink</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vrielink H, Reesink HW. Transfusion‐transmissible infections. Curr Opin Hematol 1998;5:396‐405.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>396</start><end>405</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Hematol</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>396</start><end>405</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Infection with TT virus, a novel transfusion‐transmissible DNA virus, in haemophiliacs and in blood products</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Yokozaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Toyoda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Nakano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yokozaki S, Toyoda H, Nakano I, et al. Infection with TT virus, a novel transfusion‐transmissible DNA virus, in haemophiliacs and in blood products. Br J Haematol 1999;105:1114‐9.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>105</number></detail><extent unit="pages"><start>1114</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>105</number></detail><extent unit="pages"><start>1114</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Photochemical inactivation of viruses with psoralens: an overview</title></titleInfo><name type="personal"><namePart type="given">CV</namePart><namePart type="family">Hanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hanson CV. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells 1992;18:7‐25.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>7</start><end>25</end></extent></part><relatedItem type="host"><titleInfo><title>Blood Cells</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>7</start><end>25</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Inactivation of parvovirus B19 in platelets by Helinx technology</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Sawyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Hanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Dupuis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sawyer L, Hanson D, Dupuis K. Inactivation of parvovirus B19 in platelets by Helinx technology. Transfusion 2004;44:102A.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>102A</start></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>102A</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Transmission of tick‐borne agents of disease by blood transfusion: a review of known and potential risks in the United States</title></titleInfo><name type="personal"><namePart type="given">JH</namePart><namePart type="family">McQuiston</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JE</namePart><namePart type="family">Childs</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Chamberland</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tabor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McQuiston JH, Childs JE, Chamberland ME, Tabor E. Transmission of tick‐borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000;40:274‐84.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>274</start><end>84</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>274</start><end>84</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">De Alarcon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Benjamin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Dugdale</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005;45:1362‐72.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1362</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1362</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Hambleton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Wages</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Radu‐Radulescu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hambleton J, Wages D, Radu‐Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302‐7.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1302</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1302</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) using plasma prepared with photochemical treatment (INTERCEPT plasma)</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Mintz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Neff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">MacKenzie</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mintz P, Neff A, MacKenzie M, et al. Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) using plasma prepared with photochemical treatment (INTERCEPT plasma). Blood 2004;104:239a.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>239a</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>239a</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Pathogen inactivated fresh frozen plasma prepared using HelinxTM technology is efficacious and well tolerated in treatment of end‐stage liver disease patients—the STEP AC trial</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Mintz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Steadman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Blackall</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mintz P, Steadman R, Blackall D, et al. Pathogen inactivated fresh frozen plasma prepared using HelinxTM technology is efficacious and well tolerated in treatment of end‐stage liver disease patients—the STEP AC trial. Blood 2001;98(Suppl 1):709a.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>709a</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>709a</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Preparation of cryoprecipitate from photochemically treated fresh frozen plasma</title></titleInfo><name type="personal"><namePart type="given">PD</namePart><namePart type="family">Mintz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NL</namePart><namePart type="family">Avery</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Moulaison</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mintz PD, Avery NL, Moulaison SL, et al. Preparation of cryoprecipitate from photochemically treated fresh frozen plasma. Transfusion 2000;40(Suppl 1):63S.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>63S</start></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>63S</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S‐59) and ultraviolet A light</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Yarranton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Lawrie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IJ</namePart><namePart type="family">Mackie</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yarranton H, Lawrie AS, Mackie IJ, et al. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S‐59) and ultraviolet A light. Transfusion 2005;45:1453‐8.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1453</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1453</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers</title></titleInfo><name type="personal"><namePart type="given">CV</namePart><namePart type="family">Hanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Crawford‐Miksza</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Sheppard</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hanson CV, Crawford‐Miksza L, Sheppard HW. Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol 1990;28:2030‐4.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2030</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Microbiol</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2030</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Identification of HTLV‐I‐ or HTLV‐II‐producing cells by cocultivation with BHK‐21 cells stably transfected with a LTR‐lacZ gene construct</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Astier‐Gin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Portail</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Lafond</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Guillemain</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Astier‐Gin T, Portail JP, Lafond F, Guillemain B. Identification of HTLV‐I‐ or HTLV‐II‐producing cells by cocultivation with BHK‐21 cells stably transfected with a LTR‐lacZ gene construct. J Virol Meth 1995;51:19‐29.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>19</start><end>29</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol Meth</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>19</start><end>29</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Photochemical decontamination of blood components containing hepatitis B and non‐A, non‐B virus</title></titleInfo><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Alter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Creagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Morel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alter HJ, Creagan RP, Morel PA, et al. Photochemical decontamination of blood components containing hepatitis B and non‐A, non‐B virus. Lancet 1988;2:1446‐50.</note><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>1446</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>1446</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Non‐A, non‐B hepatitis in chimpanzees and marmosets</title></titleInfo><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Feinstone</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Alter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Dienes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feinstone SM, Alter HJ, Dienes HP, et al. Non‐A, non‐B hepatitis in chimpanzees and marmosets. J Infect Dis 1981;144:588‐98.</note><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>588</start><end>98</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>588</start><end>98</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Experimental transmission of duck hepatitis B virus to Pekin ducks and to domestic geese</title></titleInfo><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Marion</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Cullen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RR</namePart><namePart type="family">Azcarraga</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marion PL, Cullen JM, Azcarraga RR, et al. Experimental transmission of duck hepatitis B virus to Pekin ducks and to domestic geese. Hepatology 1987;7:724‐31.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>724</start><end>31</end></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>724</start><end>31</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Infectious cDNA clone of the epidemic west nile virus from New York City</title></titleInfo><name type="personal"><namePart type="given">PY</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Tilgner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MK</namePart><namePart type="family">Lo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shi PY, Tilgner M, Lo MK, et al. Infectious cDNA clone of the epidemic west nile virus from New York City. J Virol 2002;76:5847‐56.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>5847</start><end>56</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>5847</start><end>56</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Photosensitized inactivation of Plasmodium falciparum‐ and Babesia divergens‐infected erythrocytes in whole blood by lipophilic pheophorbide derivatives</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Grellier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Santus</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Mouray</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grellier P, Santus R, Mouray E, et al. Photosensitized inactivation of Plasmodium falciparum‐ and Babesia divergens‐infected erythrocytes in whole blood by lipophilic pheophorbide derivatives. Vox Sang 1997;72:211‐20.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>211</start><end>20</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>211</start><end>20</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Methods for detecting Babesia microti infection in wild rodents</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Etkind</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Piesman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TK2nd</namePart><namePart type="family">Ruebush</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Etkind P, Piesman J, Ruebush TK 2nd, et al. Methods for detecting Babesia microti infection in wild rodents. J Parasitol 1980;66:107‐10.</note><part><date>1980</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>107</start><end>10</end></extent></part><relatedItem type="host"><titleInfo><title>J Parasitol</title></titleInfo><part><date>1980</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>107</start><end>10</end></extent></part></relatedItem></relatedItem><identifier type="istex">00BDD775AF6850E69CB3CAE9F34F44041508D8D5</identifier><identifier type="ark">ark:/67375/WNG-FW6611XX-V</identifier><identifier type="DOI">10.1111/j.1537-2995.2006.00867.x</identifier><identifier type="ArticleID">TRF00867</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FW6611XX-V/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:00BDD775AF6850E69CB3CAE9F34F44041508D8D5
|texte= Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function
}}
| This area was generated with Dilib version V0.6.33. |  |